Gadgeel's Preview of Key ESMO 2024 Findings in Lung Cancer

Shirish M. Gadgeel, MD, chief of division of hematology/oncology at Henry Ford Cancer Institute, Henry Ford Health in Detroit, Michigan, discusses research that he is particularly excited to see presented at the 2024 European Society for Medical Oncology (ESMO) Congress.

He starts by discussing what to expect from the overall survival data from the second interim analysis of MARIPOSA-2 (NCT04988295), and moves into what to keep an eye on at the ESMO Congress as a whole.

Transcription:

0:09 | I think [MARIPOSA-2 data are] just going to confirm the benefit that has been observed in the first 2 presentations and the publications on the MARIPOSA study [NCT04487080], that this combination does provide benefit that seems to be better and kind of in several efficacy end points. This seems to be a consistent improvement observed with this as compared [with] the previous standard or the existing standard. I think it just strengthens the case to at least discuss this option with all patients.

0:57 | I think for the last 2 or 3 years, every cancer conference has led to very important results in thoracic oncology, particularly in lung cancer. And I think there is a common theme that has been ongoing over the last, I would say, 10 years, where we are developing novel targeted therapies or combinations for treatments of patients with actionable genomic alterations in their cancers as well as further improvements in immunotherapy. I think there is a third class of drugs that has been made that has provided some encouraging data, and that is antibody-drug conjugates. I think ESMO is going to be another conference that is going to provide further data in these 3 regards. That is, better targeted therapy, better immunotherapy or immunotherapy combinations, and antibody-drug conjugates.

2:14 | I believe we are only at the beginning of these new advances, and I think in the coming years, we are going to do even better. That is the hope. I think where we are headed is going to much more treatment that is very much individualized. We have already started that journey of individualizing therapy, but we are going to be even better at individualizing therapy, so that not only patients derive the most benefit from treatment, but also they improve their quality-of-life and do not negatively impact it. So I think it is going to be both about efficacy and improving a patient's quality-of-life.